FUROSEMIDE - FRESENIUS 20 MG 2 ML

País: Israel

Idioma: anglès

Font: Ministry of Health

ingredients actius:

FUROSEMIDE

Disponible des:

NEOPHARM (ISRAEL) 1996 LTD

Codi ATC:

C03CA01

formulario farmacéutico:

SOLUTION FOR INJECTION

Composición:

FUROSEMIDE 20 MG / 2 ML

Vía de administración:

I.M, I.V

tipo de receta:

Required

Fabricat per:

LABESFAL - LABORATORIOS ALMIRO S.A, FRESENIUS KABI GROUP, PORTUGAL

Área terapéutica:

FUROSEMIDE

indicaciones terapéuticas:

Furosemide is a potent diuretic indicated for use when a prompt and effective diuresis is required.Furosemide Injection 20mg/2ml is appropriate for use in emergencies or where oral therapy is not feasible.The indications include cardiac, pulmonary, hepatic and renal oedema.

Data d'autorització:

2022-02-28

Fitxa tècnica

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
FUROSEMIDE - FRESENIUS 20 MG/ 2 ML
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml solution contains Furosemide 10 mg.
Each 2 ml ampoule contains Furosemide 20 mg.
For a full list of the excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Solution for injection.
clear, colourless to almost colourless solution.
4. CLINICAL INFORMATION
4.1. Therapeutic indications
Furosemide is a potent diuretic indicated for use when a prompt and
effective diuresis is required.
Furosemide injection 20mg/2ml is appropriate for use in emergencies or
when oral therapy is not
feasible. The indications include cardiac, pulmonary, hepatic and
renal oedema.
4.2. Posology and method of administration
Route of administration: intramuscular or intravenous use.
_ _
_Adults _
Intravenous furosemide must be injected or infused slowly; a rate of 4
mg per minute must not be
exceeded. In patients with severe impairment of renal function (serum
creatinine >5 mg/dl), it is
recommended that an infusion rate of 2.5 mg per minute is not
exceeded.
Intramuscular administration must be restricted to exceptional cases
where neither oral nor
intravenous administration is feasible. It must be noted that
intramuscular injection is not suitable for
the treatment of acute conditions such as pulmonary oedema.
To achieve optimum efficacy and suppress counterregulation, a
continuous furosemide infusion is
generally to be preferred to repeated bolus injections. Where
continuous furosemide infusion is not
feasible for follow-up treatment after one or several acute bolus
doses, a follow-up regimen with low
doses given at short intervals (approximately four hours) is to be
preferred to a regimen with higher
bolus doses at longer intervals.
Doses of 20 to 50 mg intramuscularly or intravenously may be given
initially. If larger doses are
required, they should be given by 20 mg increments and not given more
often than every two hours.
If doses greater than 50 mg are required, it is recommended that